Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a pioneering biopharmaceutical company headquartered in Vancouver, British Columbia. Focused on neurology, Xenon leverages its proprietary discovery platform, termed 'extreme genetics', to develop innovative medications. The company’s approach involves studying families with severe phenotypes to identify single-gene defects, which offer insights into human biology and serve as potential drug targets.
Xenon’s development pipeline targets a range of neurological disorders, particularly epilepsy and depression. The flagship product, XEN1101, is a potent, selective potassium channel opener currently in various phases of clinical trials for epilepsy and major depressive disorder (MDD). Xenon has ongoing Phase 3 trials for XEN1101 in focal onset seizures (X-TOLE2, X-TOLE3) and primary generalized tonic-clonic seizures (X-ACKT). The drug has shown promising efficacy in reducing seizures and improving quality of life in long-term extension studies.
Additionally, Xenon is exploring XEN1101's potential in treating MDD, with a Phase 3 program expected to begin in 2024. Recent interim data from the X-NOVA Phase 2 trial revealed significant improvements in depression symptoms, supporting further development for this indication. Xenon’s pre-clinical work includes investigations into Nav1.1 and Nav1.7 potentiators for various neurological conditions.
Key developments include a partnership with Neurocrine Biosciences to develop XEN901 (NBI-921352) for epilepsy. Xenon's financial stability, robust clinical pipeline, and strategic collaborations position it for continued growth and innovation in neurology-focused therapeutics.
Recent Achievements:
- Strong presence at AES 2023 with multiple presentations on XEN1101
- Presented new data from the Phase 2b X-TOLE trial demonstrating significant seizure freedom rates
- Expanded open-label extension study collecting over 500 patient years of data
- Announced positive topline results from X-NOVA Phase 2 trial for MDD
- Ongoing collaboration with Icahn School of Medicine for additional MDD studies
For more updates and detailed information, visit the official website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced its upcoming participation in the virtual William Blair Biotech Focus Conference 2021. This event is scheduled for Thursday, July 15, 2021, from 10 am to 10:45 am Eastern Time. Key participants include Ian Mortimer, President and CEO, and Dr. Simon Pimstone, Executive Chair of the Board. For further details and a link to the live webcast, visit Xenon’s official website. Webcasts will be available for replay post-event for 30 days. Xenon is focused on developing innovative therapies for neurological disorders.
Xenon Pharmaceuticals (NASDAQ: XENE) announced the completion of patient randomization for its XEN1101 Phase 2b 'X-TOLE' clinical trial, exceeding the original target of 300 to 326 patients. Topline results are expected between late September and mid-October 2021. The trial aims to assess the efficacy of XEN1101 for treating focal epilepsy, with the primary endpoint focusing on changes in monthly seizure frequency. A live webinar will feature leading experts discussing the trial and broader epilepsy landscape, occurring on July 12, 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) held its Annual Meeting on June 3, 2021, announcing a leadership transition with Ian Mortimer as the new CEO and Sherry Aulin as CFO. Dr. Simon Pimstone transitions to Executive Chair, recognizing the contributions of long-serving board members. Elizabeth Garofalo was elected to the board, bringing extensive experience in neurology. The company focuses on developing therapies for neurological disorders, emphasizing its pipeline targeting unmet medical needs in epilepsy.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the Jefferies 2021 Virtual Healthcare Conference on June 2, 2021, at 3:00 PM ET. The event will feature a fireside chat accessible via a live webcast. This participation highlights Xenon's commitment to advancing its pipeline of innovative therapeutics for neurological disorders, particularly focusing on epilepsy. Interested investors can find more information on the company's presentations and webcasts on their investor website. Note that the schedule is subject to change.
Xenon Pharmaceuticals reported Q1 2021 financial results, highlighting a net loss of $15.8 million, compared to $7.5 million in Q1 2020. Total revenue for the quarter was $4.4 million, down from $7.1 million year-over-year. The company completed patient screening in the Phase 2b ‘X-TOLE’ clinical trial for XEN1101 and anticipates topline data by Q3 2021. Following a public offering, Xenon bolstered its cash reserves to $274.7 million, sufficient to fund operations into 2023. The company also aims to advance multiple clinical trials targeting neurological disorders, including major depressive disorder.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will disclose its first quarter 2021 financial results on May 11, 2021, after U.S. market close. A live conference call is scheduled for 4:30 PM ET, accessible via phone or through Xenon’s investor website. The company focuses on developing innovative neurology therapies, particularly for epilepsy, with a portfolio aimed at addressing significant medical needs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in two upcoming virtual investor conferences. The first is the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 10:15 am ET, accessible via a live webcast. The second is the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 3:00 pm ET, also available through a live webcast. The company focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy. More information can be found on their investor website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in a virtual fireside chat at the Stifel 3rd Annual CNS Day on March 31, 2021, at 1:00 pm ET. The discussion will focus on the company’s innovative therapies for neurological disorders, particularly epilepsy. Investors can access the live webcast on the company's website, where it will also be archived for future viewing. The presentation times are subject to change, emphasizing the need for stakeholders to stay updated.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has successfully closed an underwritten public offering of 5,135,135 common shares, including an additional 810,810 shares from the underwriters' exercised option. The shares were priced at $18.50 each, while pre-funded warrants to purchase 1,081,081 common shares were offered at $18.4999. The total gross proceeds from the offering are approximately $115.0 million, before deductions. Jefferies, Stifel, and William Blair acted as joint book-running managers for the offering.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced a public offering of 4,324,325 common shares priced at $18.50 each, alongside pre-funded warrants for 1,081,081 common shares at $18.4999. The offering aims to raise approximately $100 million before deductions. An additional option for underwriters to purchase 810,810 shares exists for 30 days. The offering is anticipated to close around March 12, 2021, subject to standard conditions. Jefferies, Stifel, and William Blair are leading the offering, with further details available through their channels.
FAQ
What is the current stock price of Xenon Pharmaceuticals (XENE)?
What is the market cap of Xenon Pharmaceuticals (XENE)?
What does Xenon Pharmaceuticals specialize in?
What is the focus of Xenon’s proprietary discovery platform?
What is XEN1101?
What are the recent achievements of Xenon Pharmaceuticals?
Who are Xenon’s strategic partners?
What are Xenon’s key products in the pipeline?
What is the status of the XEN1101 epilepsy trials?
How can I contact Xenon Pharmaceuticals for investor information?
Where is Xenon Pharmaceuticals headquartered?
What is the significance of Xenon’s pre-clinical work?
